AMPEDRNA BIOSCIENCES LLC

Biotech · Private

RNA-based therapeutic cancer vaccine for HPV-related cancers designed to boost immunotherapy response

Grants
$399K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Highly stable mini-circRNA vaccine with maximally activated and long-lasting T cells for HPV-related cancer combination immunotherapy$398,823
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2409AXENT BIOSCIENCES INC.——
2410CELLGRO TECHNOLOGIES, LLC——
2411GLAX, LLC——
2412AMPEDRNA BIOSCIENCES LLC——
2413SURVEY GENOMICS, INC.——
2414ATLAS BIOLOGICS, LLC——
2415TRIPILL BIOTECHNOLOGY, CORP.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.